Evolus (EOLS) vs Ironwood Pharmaceuticals (IRWD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ironwood Pharmaceuticals (IRWD) has outperformed Evolus (EOLS) over the past year, gaining 144.9% versus a gain of 25.6%. Over five years, EOLS leads with a +1.7% price change compared with -71.7% for IRWD. Ironwood Pharmaceuticals is the larger company by market cap ($644.4 million vs $510.6 million), about 1.3 times the size.
On valuation, Ironwood Pharmaceuticals trades at a lower forward P/E (2.6x vs 26.4x for Evolus).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EOLS | IRWD |
|---|---|---|
| Share price | $7.73 | $3.90 |
| Market cap | $510.57M | $644.44M |
| 1-day change | -0.90% | +0.78% |
| YTD return | +17.29% | +14.84% |
| 1-year return | +25.60% | +144.94% |
| 5-year return | +1.69% | -71.67% |
| P/E ratio (TTM) | — | 5.06 |
| Forward P/E | 26.43 | 2.60 |
| EPS (TTM) | $-0.53 | $0.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.31 | $5.78 |
| 52-week low | $3.86 | $1.41 |
| Distance from 52-week high | -16.97% | -32.53% |
| Analyst consensus | none | none |
| Avg. price target upside | +94.05% | +56.41% |
| Average volume | 900.79K | 2.02M |
| Shares outstanding | 66.05M | 165.24M |
| Employees | 353 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRWD has outperformed EOLS by 119.3 percentage points over the past year.
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 353 employees
About Ironwood Pharmaceuticals
IRWD stock →Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
EOLS vs IRWD FAQ
Which is bigger, Evolus or Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals (IRWD) is larger, with a market capitalization of $644.44M compared with $510.57M for Evolus (EOLS).
Which stock has performed better over the past year, EOLS or IRWD?
IRWD returned +144.94% over the past 12 months, compared with +25.60% for EOLS (price return, excluding dividends). Past performance does not predict future results.
Are Evolus and Ironwood Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.